Volume 14, Number 4—April 2008
Synopsis
Potential Use of Antiviral Agents in Polio Eradication
Armando M. De Palma*, Gerhard Pürstinger†, Eva Wimmer†, Amy K. Patick‡, Koen Andries§, Bart Rombaut¶, Erik De Clercq*, and Johan Neyts*
Table
Inhibitory activity of selected compounds against replication of poliovirus Sabin strains 1, 2, and 3 in HeLa cells, as determined by a CPE reduction assay*
| Compound | EC50 (µmol/L) |
Toxicity (CC50;µmol/L) | TI (min–max) | ||
|---|---|---|---|---|---|
| PV1 | PV2 | PV3 | |||
| Capsid binders | |||||
| Pirodavir analog (R78206) | 0.76 ± 0.18 | 0.22 ± 0.19 | 0.11 ± 0.10 | 27 ± 34 | 35–245 |
| Pleconaril | >100 | 1.1 ± 0.6 | 0.22 ± 0.15 | 66 ± 6 | <0.66–300 |
| Pirodavir (R77975) |
10 ± 1 |
1.7 ± 0.1 |
0.56 ± 0.03 |
>100 |
>10–>179 |
| Protease inhibitors | |||||
| Rupintrivir | 0.022 ± 0.028 | 0.041 ± 0.024 | 0.0052 ± 0.0046 | >100 | >2,439–>19,231 |
| Compound 1 |
0.26 ± 0.24 |
0.31 ± 0 .21 |
0.060 ± 0 .000 |
>100 |
>322–>1,667 |
| 3A inhibitor | |||||
| Enviroxime |
0.2 ± 0.25 |
0.056 ± 0.020 |
0.035 ± 0.029 |
58 ± 6 |
290–1,657 |
| Nucleoside analogs | |||||
| Ribavirin | 57 ± 13 | 64 ± 4 | 55 ± 7 | >100 | >1.6–>1.8 |
| 2'-C-methylcytidine† | 15 ± 18 | 29 ± 27 | 3.9 ± 2.3 | >100 | >3.4–>26 |
| 2'-C-methyladenosine | 5.5 ± 0.0 | 5.6 ± 0.1 | 5.4 ± 0.4 | 84 ± 0 | 15 |
| 4’-azidocytidine |
>100 |
>100 |
>100 |
>100 |
><1 |
| 2C inhibitors | |||||
| HBB | 300 ± 68 | 225 ± 128 | 295 ± 88 | >400 | >1.3–>1.8 |
| MRL-1237 |
5.3 ± 0.3 |
4.6 ± 1.4 |
3.8 ± 2.5 |
>100 |
>19–>26 |
| Unknown target | |||||
| MDL-860 | 6.0 ± 1.6 | 3.6 ± 2.2 | 2.2 ± 1.5 | >100 | >17–>45 |
*CPE, cytopathic effect; EC50, 50% effective concentration; CC50, 50% cytotoxic concentration; PV, poliovirus; TI, therapeutic index (CC50/EC50); min, minimum; max, maximum; HBB, 2-(α-hydroxybenzyl)-benzimidazole.
†Valopicitabine (oral valine ester prodrug of 2′-C-methylcytidine).
Page created: July 16, 2010
Page updated: July 16, 2010
Page reviewed: July 16, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.